Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway
Authors
Keywords
Melanoma, BRAF, EGFR, Erlotinib, Vemurafenib
Journal
Targeted Oncology
Volume 10, Issue 1, Pages 77-84
Publisher
Springer Nature
Online
2014-05-14
DOI
10.1007/s11523-014-0318-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032
- (2015) Elisabetta Vergani et al. NEOPLASIA
- First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments
- (2013) Bin-Chi Liao et al. DRUGS
- Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
- (2013) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells
- (2012) Hiu‑Fung Yuen et al. BIOSCIENCE REPORTS
- Abstract 2772: AT13387, an HSP90 inhibitor, is effective in both vemurafenib-sensitive and -resistant melanoma models:
- (2012) Ana M. Rodriguez-Lopez et al. CANCER RESEARCH
- Epidermal Growth Factor Facilitates Melanoma Lymph Node Metastasis by Influencing Tumor Lymphangiogenesis
- (2012) Andreas Bracher et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor
- (2012) Jae-Kyung Won et al. Journal of Molecular Cell Biology
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- (2012) Maria R. Girotti et al. Cancer Discovery
- Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
- (2012) Matthew A. Held et al. Cancer Discovery
- Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism
- (2011) Irene Sánchez-Hernández et al. CANCER LETTERS
- Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
- (2011) F. Su et al. CANCER RESEARCH
- EGFR in melanoma: clinical significance and potential therapeutic target
- (2011) Barbara Boone et al. JOURNAL OF CUTANEOUS PATHOLOGY
- A phase II study of gefitinib in patients with metastatic melanoma
- (2011) Sapna P. Patel et al. MELANOMA RESEARCH
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
- (2011) Mohammad Atefi et al. PLoS One
- MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720
- (2010) C. C. Jiang et al. CLINICAL CANCER RESEARCH
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma
- (2009) N. Schicher et al. CLINICAL CANCER RESEARCH
- ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839)
- (2009) Emelie A. Djerf et al. MELANOMA RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now